Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy

Figure 1 Comparison of hepatic encephalopathy events, hepatic encephalopathy-related hospitalizations and length of hepatic encephalopathy-related hospitalization with or without rifaximin for entire cohort and subgroups “prevention of recurrent hepatic encephalopathy” and “prevention of an acute episode on persistent hepatic encephalopathy”. A: Entire cohort; B: Prevention of recurrent hepatic encephalopathy (HE) episodes; C: Prevention of recurrent acute exacerbations on persistent HE. The results are expressed for 100 d of follow-up. HE: Hepatic encephalopathy.

Figure 2 Probability of hepatic encephalopathy recurrence during rifaximin therapy in the subgroup “Prevention of recurrent hepatic encephalopathy”, n = 29; Kaplan-Meier method. ¹Censored data correspond to discontinuation of treatment before the occurrence of hepatic encephalopathy (HE). At the end of follow-up, it corresponded to “HE-free” patients, after six months of treatment.

Figure 3 Cessation probability of persistent hepatic encephalopathy during rifaximin therapy in the subgroup “Prevention of an acute episode on persistent hepatic encephalopathy”, n = 33; Kaplan-Meier method. ¹Censored data correspond to discontinuation of treatment before cessation of hepatic encephalopathy (HE). At the end of follow-up, it corresponded to patients with maintenance of persistent HE.